WARF: P02358US

Tn5 Transposase Showing Enhanced Activity


William Reznikoff, Mindy Steiniger-White, Jeremy Metzler

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing Tn5 transposase mutants with high transposition rates.
OVERVIEWThe low mobility of bacterial transposons, such as Tn5, makes it difficult for researchers to detail the molecular transposition process and to exploit transposition for uses such as the development of new diagnostic and therapeutic resources.
THE INVENTIONUW-Madison researchers have developed Tn5 transposase (Tnp) mutants with higher transposase activities than either the wild-type Tnp or their previously developed hyperactive Tnp mutants. These new mutants are modified at several amino acids so that they have greater affinity for a Tn5 outside end sequence than wild-type Tnp.
  • May be used to form a synaptic complex in vitro that could be used to make an insertional mutation at a random position in nucleic acid
  • Useful in a variety of other in vitro and in vivo transposition applications
  • Show higher transposition rate than wild-type transposase or a previously developed hyperactive mutant transposase
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.